RecruitingNCT05916339
Methylphenidate or amphetamine, followed by next-step medication, for ADHD in autistic youth
About this title
Read the official source — NCT05916339Medication studyAges 4–17United States + Canada
Understand this study
Who could participate?
Listed age limits: 4 years to 17 years.
- Listed locations
- Irvine and 12 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 1, 2023
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 500
- Sponsor
- Daniel Coury
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States, Canada
- Age range
- From 4 Years to 17 Years
- Official registry ID
- NCT05916339
- Official title
Show the full official title
Comparative Effectiveness of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Irvine, United States · Los Angeles, United States · Portland, United States
10 more locations
- Boston, United States
- Rochester, United States
- Cincinnati, United States
- Columbus, United States
- Philadelphia, United States
- Pittsburgh, United States
- Greenville, United States
- Charlottesville, United States
- Edmonton, Canada
- Toronto, Canada
Questions about this study
Who is behind this study?
The study sponsor is Daniel Coury.
Does this study involve medication?
Yes. The study involves medication, including Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant..
Who can participate?
Listed age limits: 4 years to 17 years.
Is this study still recruiting?
The registry lists this study as recruiting.
